New daily persistent headache: the complete patient guide (UK-focus)

New daily persistent headache is one of the least understood and most treatment-resistant headache conditions. This is an attempt to explain what it is, what causes it, what treatments exist, and how to navigate the NHS to access them. Written from the perspective of someone living with it.

You had a virus, or a stressful period, or nothing you can identify at all. One day a headache started and it never stopped. Not a migraine that comes and goes. Not a bad week that resolves. A headache that arrived on a specific, memorable day, became constant within hours, and has been there every day since.

If that description fits, you may have new daily persistent headache, or NDPH. You may also have spent months or years trying to get anyone to take it seriously, because your blood tests are normal, your MRI is normal, and the condition itself is so poorly known that many GPs and even some neurologists have never encountered it.

This guide is an attempt to put everything a UK patient needs to know in one place. It is not medical advice. It is one person’s reading of the evidence, combined with personal experience of navigating this condition through the NHS.

What NDPH is

NDPH is classified in the International Classification of Headache Disorders (ICHD-3) under “other primary headache disorders.” The formal diagnostic criteria require a persistent headache with a distinct and clearly remembered onset, where pain becomes continuous and unremitting within 24 hours, present for more than three months, and not better explained by another diagnosis.

In plain language: you can pinpoint when this headache started. It was daily from the beginning, or became daily within a day. It hasn’t gone away. And nothing else explains it.

That last criterion matters. NDPH is a diagnosis of exclusion in part. Before it can be diagnosed, secondary causes need to be investigated and ruled out. An MRI is standard to exclude structural problems. In some cases, lumbar puncture may be needed to rule out disorders of cerebrospinal fluid pressure (both too high, as in idiopathic intracranial hypertension, and too low, as in spontaneous intracranial hypotension). Blood tests should exclude metabolic and inflammatory causes. Only when these come back clear can NDPH be considered.

The ICHD-3 notes something unusual about NDPH: patients “invariably recall and can accurately describe” the onset. If you cannot do so, the classification says another diagnosis should be made. This specificity of onset memory is one of the features that distinguishes NDPH from chronic migraine or chronic tension-type headache, both of which typically evolve gradually over months from an episodic pattern.

Is NDPH actually a condition?

This is a live question in headache medicine, and it is worth being honest about. There is a credible argument that NDPH is better understood as a syndrome or description than as a distinct disease entity.

The reasoning goes like this: NDPH is defined entirely by its pattern of onset (sudden, daily, persistent) rather than by a specific mechanism. It has no biomarker, no diagnostic test, and no characteristic pathophysiology that distinguishes it from other chronic headaches once established. The pain itself can be migraine-like or tension-type-like, or a combination of both. Two people with NDPH may have entirely different underlying mechanisms driving their headache.

Some researchers have suggested that a significant proportion of “primary” NDPH may actually be secondary headache with an unidentified cause. The argument is that something must have happened to turn on the switch from no headache to daily persistent headache, and the fact that we cannot always identify the trigger does not mean one does not exist. In a 2023 review, Peng and Rozen suggested that NDPH should perhaps be reclassified as a syndrome with subtypes defined by the triggering event, rather than treated as a single diagnostic entity.

This debate matters clinically because it affects how the condition is treated. If NDPH is a single entity, it makes sense to search for a single treatment. If it is a syndrome with multiple underlying causes, the right treatment depends on identifying which cause is operating in a given patient.

For the person living with it, though, the philosophical question is less important than the practical reality: you have a daily headache that started suddenly and has not stopped. Whether it is called NDPH, a syndrome, or a description, the pain is the same, the impact on your life is the same, and the need for effective management is the same. The label matters most when it comes to accessing treatment through clinical pathways, which is where having a recognised diagnostic code helps.

What causes it

The short answer is that the cause is unknown and likely varies between patients. The longer answer involves several plausible mechanisms, none of which is established beyond doubt.

Post-infectious onset is the most commonly identified trigger. Between 30% and 80% of NDPH patients in various studies report that their headache began during or shortly after a viral illness. Epstein-Barr virus, herpes simplex virus, cytomegalovirus, and upper respiratory infections have all been implicated. Since the pandemic, COVID-19 has become one of the most frequently reported triggers. NDPH-like presentations were observed as early as the 1890 Russian flu pandemic, suggesting that post-infectious persistent headache is not new, even if the terminology is.

The mechanism by which a virus triggers a persistent headache is not fully understood. The leading hypothesis involves neuroinflammation: the immune response to the virus triggers release of pro-inflammatory cytokines (particularly tumour necrosis factor alpha, which has been found elevated in the cerebrospinal fluid of NDPH patients) that activate and sensitise the trigeminovascular pain pathways. In some patients, this inflammatory state may become self-sustaining, persisting long after the initial infection has cleared. This overlaps with the broader picture of post-viral autonomic dysfunction and shares mechanistic features with ME/CFS and long COVID.

Stressful life events are the second most commonly reported trigger. Whether stress directly causes NDPH or acts as a cofactor alongside subclinical infection or other vulnerability is unclear.

No identifiable trigger applies to a significant minority of patients. In some studies, up to 80% of patients could not identify a precipitating event. This does not mean the headache is unexplained in principle, only that the trigger was not identified or was not clinically apparent.

Other proposed mechanisms include cervical joint hypermobility, defective internal jugular venous drainage, and autoimmune processes. The honest summary is that NDPH likely represents a final common pathway that can be reached through several different routes, which is part of why it is so difficult to treat.

What it feels like and how it overlaps with other headache types

NDPH does not have a characteristic pain quality. The ICHD-3 explicitly states that “the pain lacks characteristic features, and may be migraine-like or tension-type-like, or have elements of both.” This is unusual for a headache diagnosis and contributes to the diagnostic confusion.

In practice, most patients seen at specialist headache centres present with migraine-like features: nausea, photophobia, phonophobia, and a throbbing or pulsating quality at least some of the time. But the baseline is often a constant dull, pressing, or tightening pain that sits behind or around the eyes, across the forehead, or diffusely across the head. The pain typically fluctuates in intensity throughout the day, with periods of worsening that can feel like distinct attacks superimposed on the constant background.

Some patients have a strictly unilateral headache, always on the same side. This is important because it raises the possibility of a different diagnosis.

Hemicrania continua

Hemicrania continua is a continuous, unilateral headache that responds completely to indomethacin. It is classified separately from NDPH in the ICHD-3, and when the criteria for both are met, hemicrania continua takes diagnostic priority. The practical significance is that hemicrania continua has a specific and often highly effective treatment, while NDPH does not.

An indomethacin trial is therefore worth doing for anyone with a persistent unilateral headache, even if the presentation otherwise fits NDPH. The standard trial involves starting at 25mg three times daily with food, escalating to 50mg three times daily and then 75mg three times daily if there is no response at lower doses, with a proton pump inhibitor for gastric protection. If indomethacin produces a clear and complete resolution of the headache, the diagnosis is hemicrania continua. If it does not, the diagnosis is not hemicrania continua, and the indomethacin should be stopped.

In my own case, a headache specialist recommended this trial because my pain is consistently right-sided. The indomethacin had no effect at any dose, which ruled out hemicrania continua and left NDPH with migrainous features as the working diagnosis.

Chronic migraine and chronic tension-type headache

The distinction between NDPH and chronic migraine or chronic tension-type headache is primarily about the pattern of onset, not the character of the pain. Chronic migraine evolves gradually from episodic migraine over months or years, with increasing frequency until the headache is present on 15 or more days per month. NDPH, by contrast, is daily from the outset.

This distinction can be clinically important because some treatments that work well for chronic migraine (particularly Botox and CGRP inhibitors, which have been trialled in large chronic migraine populations) may be less effective for NDPH. However, in practice, many clinicians treat NDPH based on its dominant phenotype: if the pain is migraine-like, migraine treatments are tried; if tension-type-like, treatments used for tension-type headache are tried.

Medication overuse headache

Anyone who has had a persistent headache for months and has taken regular painkillers needs to consider whether medication overuse headache (MOH) is part of the picture. MOH can develop from regular use of simple analgesics (paracetamol, ibuprofen) on 15 or more days per month, or triptans or opioids on 10 or more days per month.

The complicating factor with NDPH is that medication overuse may have developed secondary to the original headache. The ICHD-3 allows both diagnoses to coexist when the onset of daily headache clearly predates the medication overuse. But if there is any uncertainty, addressing the overuse component first is usually necessary before the underlying headache can be properly assessed.

One small consolation for NDPH patients: because acute painkillers are generally ineffective for the constant background pain, many NDPH patients use less acute medication than chronic migraine patients, making medication overuse less common in this group.

Treatments

There are no randomised controlled trials of any treatment specifically for NDPH. Every treatment used for NDPH is borrowed from migraine or tension-type headache management, based on the assumption that shared mechanisms justify shared treatments. This is a reasonable approach, but it means that the evidence base is indirect, and response rates in NDPH are generally lower than in the conditions the treatments were designed for.

Preventive medications

The standard approach is sequential trials of preventive medications from different pharmacological classes. Each trial should be at an adequate dose for an adequate duration (typically at least 8 to 12 weeks at the target dose) before being judged ineffective.

Amitriptyline is a tricyclic antidepressant commonly used as a first-line headache preventive. In a UK study of NDPH patients at a specialist headache centre, the closely related drug dosulepin was found to be the most effective treatment, with a response rate of around 46%, though dosulepin is now rarely prescribed in the UK because of toxicity concerns in overdose. Amitriptyline is the standard alternative. Typical doses for headache prevention range from 10mg to 75mg at night. Side effects include drowsiness (which can be useful if sleep is disrupted), dry mouth, weight gain, and constipation. Amitriptyline is discussed further in the context of autonomic dysfunction trade-offs in the amitriptyline, propranolol, and candesartan evidence review.

Propranolol is a beta-blocker used as a migraine preventive. It is typically started at 10mg twice daily and increased gradually to 40 to 80mg daily. It is generally well tolerated but can cause fatigue, vivid dreams, and exercise intolerance. It is contraindicated in asthma. For people with post-viral autonomic dysfunction, propranolol’s blood pressure-lowering and exercise-limiting effects may be significant, and ivabradine may be a better-tolerated alternative where heart rate rather than headache is the primary target.

Candesartan is an angiotensin receptor blocker with evidence for migraine prevention. The starting dose is typically 2mg, titrated gradually toward a target of 8 to 16mg with blood pressure and renal function monitoring. It is generally well tolerated. One important caveat: a UK study identified that the presence of a daily continuous headache was a negative predictor of response to candesartan, which may temper expectations for NDPH specifically. Full discussion in the amitriptyline, propranolol, and candesartan evidence review.

Topiramate is an anticonvulsant with strong evidence for episodic migraine prevention. It carries a significant side effect burden including cognitive dulling (“brain fog”), weight loss, paraesthesia, and mood changes. It requires a pregnancy prevention programme. Some patients find it effective; others find the cognitive effects intolerable.

Other medications that may be tried include gabapentin, pregabalin, venlafaxine, and nortriptyline. The choice is typically guided by the patient’s symptom profile, comorbidities, and tolerance of side effects.

Supplements

Four supplements are commonly recommended alongside or before prescription preventives, based on their evidence in migraine prevention. The evidence for each in NDPH specifically does not exist; the rationale is extrapolation from migraine data on the basis of shared mechanisms.

Riboflavin (vitamin B2) at 400mg daily has the strongest evidence of the four, with an RCT showing a 50% or greater reduction in migraine frequency in 59% of patients. It is safe, well tolerated, and the only notable effect is bright yellow urine.

Magnesium at 400 to 600mg daily (glycinate, citrate, or malate forms are better absorbed than oxide) has evidence for reducing migraine frequency. It may also help with sleep quality and muscle tension. The main side effect is loose stools at higher doses.

Coenzyme Q10 at 100 to 300mg daily has more limited evidence than riboflavin or magnesium but is generally well tolerated. Both riboflavin and CoQ10 target mitochondrial function, and there is a rationale for using them together.

Vitamin D at 2,000 to 4,000 IU daily is primarily relevant for correcting deficiency, which is common in the UK and particularly common in people with chronic conditions who spend less time outdoors. The evidence for vitamin D specifically improving headache is strongest in people who are actually deficient. A blood test to check levels before committing to a long-term dose is worth doing.

These supplements are covered in more detail in the supplements for chronic headache prevention post.

The NHS pathway: what happens after first-line treatments

In the NHS, headache preventive treatment typically follows a stepped pathway. Three preventive medications from different pharmacological classes should be tried at adequate doses for adequate durations before a patient is considered for secondary care treatments. This is not an arbitrary bureaucratic hurdle; it reflects the NICE technology appraisal criteria for more expensive treatments and the clinical reality that some patients do respond to oral preventives when the right one is found.

The three preventive classes most commonly tried in primary care are tricyclic antidepressants (amitriptyline), beta-blockers (propranolol), and either an anticonvulsant (topiramate) or an angiotensin receptor blocker (candesartan). A GP or the National Migraine Centre (a UK charity offering specialist headache consultations) can prescribe all of these.

If three preventives have been tried and failed, the next step is referral to secondary care neurology or a specialist headache service. This unlocks access to treatments that cannot be initiated in primary care.

Botox (onabotulinumtoxin A) is NICE-approved for chronic migraine (headache on 15 or more days per month, with migraine features on at least 8 of those days) in patients who have failed three prior preventives. It involves 31 injections around the head and shoulders every 12 weeks. It is not licensed for NDPH specifically, but many NDPH patients with migraine-like features meet the chronic migraine criteria and can be treated under those guidelines. Response is variable; some patients find it transformative while others see no benefit.

CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) are NICE-approved for migraine prevention in patients who have failed three prior preventives. They are migraine-specific treatments targeting calcitonin gene-related peptide, a key neuropeptide in migraine pathophysiology. They are generally well tolerated with few side effects and are self-injected monthly. However, their evidence base is almost entirely in episodic and chronic migraine rather than NDPH, and some research suggests that the presence of a daily continuous headache pattern may predict poorer response. They remain an option worth discussing with a specialist, but expectations for NDPH should be tempered.

CGRP small molecule antagonists (gepants) such as atogepant and rimegepant are newer oral options also requiring prior failure of three preventives. Similar caveats about NDPH-specific evidence apply.

Greater occipital nerve blocks involve injection of local anaesthetic (sometimes with corticosteroid) around the greater occipital nerve at the back of the head. They can be performed in secondary care and provide temporary relief in some patients. One study found that NDPH patients without migraine features responded to nerve blocks more often (89%) than those with migraine features (43%), though the evidence base is small.

Other secondary care options include IV dihydroergotamine infusion protocols, IV lidocaine, and neuromodulation devices. These are typically reserved for the most refractory cases and are only available at specialist headache centres.

What is not recommended

Codeine and other opioids should be avoided in persistent headache. They are ineffective for the underlying condition, carry significant dependency risk, and can rapidly cause medication overuse headache. If you are currently taking codeine regularly, discussing a withdrawal plan with your GP is important.

Pushing through without treatment is not neutral. Some evidence suggests that early pharmacological treatment within the first 6 to 12 months of NDPH onset is associated with better long-term outcomes. An Italian paediatric study found that patients who received no pharmacological treatment had worse outcomes than those who were treated, even when the treatments used were not highly effective. This does not prove causation, but it does suggest that passive waiting may not be the best strategy.

Getting diagnosed and treated in the UK

The NHS is not well set up for NDPH. Most GPs have not encountered it. The condition does not appear in the Quality and Outcomes Framework, there is no specific NHS pathway for it, and the NHS.uk website has no page on NDPH. The average diagnostic delay for POTS is 4 to 8 years across multiple providers; for NDPH, anecdotal reports suggest similar or longer delays, often because the diagnosis is simply not considered.

If you think you have NDPH, these steps may help.

Start with your GP and bring specific information: the date your headache started, its daily pattern, associated symptoms, what you have tried, and what has and has not helped. Preparing for health appointments covers this in more detail. Ask explicitly about NDPH. If your GP is not familiar with it, the ICHD-3 criteria (section 4.10) are publicly available and can be shared.

If the headache is unilateral, ask about an indomethacin trial to rule out hemicrania continua. This can be prescribed by your GP with a proton pump inhibitor for gastric protection.

Work through the preventive medication ladder with your GP or through the National Migraine Centre. Three adequate trials of different preventive classes are needed before secondary care treatments become available.

If three preventives have failed, push for a neurology or headache clinic referral. Some neurology services will not accept a referral unless three preventives have been tried, so documenting what you have taken, at what dose, for how long, and why it was stopped is important. What I wish I’d known earlier covers the documenting and self-advocacy side of this.

Consider the National Migraine Centre as a parallel route. It is a charity that offers specialist headache consultations across the UK, usually by video. Free appointments are available, though the wait is longer; paid consultations are also offered and are significantly cheaper than private neurology. The clinicians are headache specialists who can prescribe the full range of first-line preventives and provide the kind of structured treatment plan that can then be implemented through your GP. Their recommendation letters carry weight with NHS services.

Prognosis

The evidence on NDPH prognosis is limited, drawn from small studies at specialist centres, and hard to generalise to any individual case.

Early studies by Vanast found that 78% of patients were pain-free within 24 months without treatment, but subsequent research from specialist headache centres (which inevitably see the most difficult cases) has been less encouraging. Robbins et al. found that 76% of their 71 patients had the persisting subtype, with continuous headache from onset. About 15% had a remitting course, and 8% had a relapsing-remitting pattern. A Japanese study of 30 patients found that treatment was judged “not effective” in 50% of cases. It is difficult to know how representative these numbers are, since people whose headaches resolve may never reach specialist services and therefore never appear in the data.

Some studies suggest that an identifiable trigger (particularly a post-infectious onset) and early treatment within the first 6 to 12 months may be associated with better outcomes. An Italian paediatric study found higher initial response rates in children than in adults, though some later relapsed. But these findings come from small, often retrospective studies, and it would be wrong to read them as confident predictions.

What can reasonably be said is that NDPH is widely described in the literature as one of the most treatment-resistant primary headache disorders, and that many patients try multiple medications without finding significant relief. Some patients do improve over time, whether through treatment, natural history, or both. The honest position is that the trajectory is uncertain for any individual, and the evidence base is not strong enough to offer reliable prognostic guidance. That uncertainty is difficult to live with, but it also means that negative outcomes are not guaranteed.

The connection to post-viral conditions

For patients whose NDPH began after a viral illness, the headache may be one component of a broader post-viral syndrome. Post-viral autonomic dysfunction, fatigue, cognitive impairment, and exercise intolerance can all co-occur. Research has documented that 87 to 96% of POTS patients experience headaches, and migraine is found in 36 to 65%. The overlap between NDPH, POTS, and ME/CFS is significant and increasingly recognised; the overlapping conditions overview covers this in more detail.

If you have NDPH alongside symptoms of orthostatic intolerance (racing heart on standing, dizziness, fatigue worse upright), it is worth investigating the autonomic component separately. The management approaches are different, and treating the autonomic dysfunction may indirectly improve the headache, particularly if the headache worsens with standing or exertion. The 30 bpm threshold article explains what orthostatic tachycardia is and how it is assessed. The COMPASS-31 is a useful screening tool for autonomic symptoms, and the NASA lean test can give you a preliminary picture of your orthostatic response at home.

If fatigue and post-exertional malaise are part of the picture alongside the headache, pacing principles apply; pushing through to exercise when post-exertional malaise is present can set recovery back.

Living with it

NDPH is relentless in a way that episodic conditions are not. There is no pain-free interval. No good days in the sense that a migraine sufferer has good days. The baseline is always present, fluctuating in intensity but never absent. This has consequences for mental health, work capacity, relationships, and the ability to plan.

The psychological impact is compounded by the diagnostic difficulty. Being told repeatedly that tests are normal, that nothing is wrong, or that the problem is anxiety (it is not, though anxiety can certainly develop secondary to chronic pain) is exhausting and demoralising. Understanding that normal tests do not mean the pain is not real, and that the condition has a recognised diagnostic classification even if it is poorly understood, can help with the sense of legitimacy that many NDPH patients lack.

Tracking symptoms consistently, including headache intensity, triggers, medication use, and autonomic readings like standing heart rate, builds the kind of documented record that is useful both clinically (when advocating for yourself at appointments) and personally (for identifying patterns). The Fatigue Severity Scale and COMPASS-31 are two tools worth completing and bringing to appointments. The NHS navigation guides on this site cover the practical side of advocating for yourself within a system that is not designed for conditions like this.

References

International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. Section 4.10.

Yamani N, Olesen J. New daily persistent headache: a systematic review on an enigmatic disorder. J Headache Pain. 2019;20(1):80.

Cheema S, Mehta D, Ray JC, Hutton EJ, Matharu MS. New daily persistent headache: a systematic review and meta-analysis. Cephalalgia. 2023;43(5):3331024231168089.

Peng KP, Rozen TD. Update in the understanding of new daily persistent headache. Cephalalgia. 2023;43(1):03331024221146314.

Goadsby PJ. New daily persistent headache: a syndrome, not a discrete disorder. Headache. 2011;51(4):650–653.

Robbins MS, Grosberg BM, Napchan U, Crystal SC, Lipton RB. Clinical and prognostic subforms of new daily-persistent headache. Neurology. 2010;74(17):1358–1364.

Prakash S, Shah ND. Post-infectious new daily persistent headache may respond to intravenous methylprednisolone. J Headache Pain. 2010;11:59–66.

Takase Y, Nakano M, Tatsumi C, Matsuyama T. Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan. Cephalalgia. 2004;24(11):955–959.

National Institute for Health and Care Excellence. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. Technology Appraisal Guidance TA260. 2012.

National Institute for Health and Care Excellence. Fremanezumab for preventing migraine. Technology Appraisal Guidance TA764 (replacing TA631). 2022.

National Institute for Health and Care Excellence. Erenumab for preventing migraine. Technology Appraisal Guidance TA682. 2021.